EUDA Health (NASDAQ: EUDA) debuts Regenixé stem cell secretome mask
Rhea-AI Filing Summary
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
Positive
- None.
Negative
- None.
Insights
EUDA adds a premium skincare product leveraging exclusive distribution rights.
EUDA Health is broadening its Helixé portfolio with the Regenixé Mask, built on iPSC-derived skin stem cell secretome technology. This positions the company within the premium beauty and wellness segment while using an existing biotech partnership with Chemokine.
The press release highlights industry data showing the global face mask market at about US$7.95 billion in 2026, forecast to reach US$9.08 billion by 2031, with Asia-Pacific as a key region. This underpins management’s interest in skincare alongside its non-invasive healthcare focus.
Execution will depend on how effectively EUDA uses its distribution networks and wellness partnerships in Malaysia and China to scale Regenixé Mask sales and expand Helixé products across Asia-Pacific. Future company filings may provide clarity on revenue contribution and uptake.
Key Figures
Key Terms
iPSC-derived skin stem cell secretome technical
cellulose mask technology technical
exclusive global distributorship rights financial
non-invasive healthcare provider financial
forward-looking statements regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-40678
EUDA Health Holdings Limited
(Exact Name of Registrant as Specified in its Charter)
60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: +65 6327 1110
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Other Events.
On June 1, 2026, EUDA Health Holdings Limited issued the press release filed herewith as Exhibit 99.1.
Exhibits
| 99.1 | Press release dated June 1, 2026. |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| Dated: June 1, 2026 | ||
| EUDA Health Holdings Limited | ||
| By: | /s/ Alfred Lim | |
| Name: | Alfred Lim | |
| Title: | Chief Executive Officer | |
| 3 |
Exhibit 99.1
EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask
SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).
EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements and gene-modulating formulations.
Regenixé Mask is formulated with iPSC-derived skin stem cell secretome technology and cellulose mask technology designed to support skin hydration, brightening, and overall recovery. EUDA believes secretome-based skincare products represent a growing category within the premium beauty and wellness market. According to Mordor Intelligence’s Face Mask Market Report, the global face mask market is estimated to be approximately US$7.95 billion in 2026 and is forecast to reach approximately US$9.08 billion by 2031, driven by growing consumer demand for skincare, beauty, and wellness products. Asia-Pacific remains one of the largest regions for facial masks and skincare products, led by demand from China, South Korea, Japan, and Southeast Asia.
EUDA intends to leverage its established distribution networks and regional wellness partnerships in Malaysia and China to drive sales and distribution of the Regenixé Mask and expand the broader Helixé product line across the Asia-Pacific region.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over approximately 1.8 billion people across the region which are experiencing significant demographic shifts as more than approximately 30% of the population ages rapidly. EUDA believes that by offering innovative, accessible, and science-backed health solutions, it is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
Certain statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Any statements that refer to expectations or other characterizations of future events, circumstances or results are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The factors may include, but not be limited to, factors related to the Company’s anticipated growth strategies, future business development, ability to develop new products, expand to other related industries or markets, and other information detailed from time to time in the filings and future filings with the United States Securities and Exchange Commission. The views expressed are those of management and are based on currently available information. Estimates and projections contained herein have been prepared by management and involve significant elements of subjective judgment and analysis and are based on certain assumptions. No representation nor warranty, expressed or implied, is made as to the accuracy or completeness of the information contained in this document, and nothing contained herein is, or shall be relied upon, as a promise or representation, whether as to the past or the future. You are cautioned not to place undue reliance on these forward-looking statements.
This press release is intended solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy the Company’s stock. This press release is based upon information available to the public, as well as other information from sources which management believes to be reliable, but is not guaranteed by the Company as being accurate nor does it purport to be complete. Opinions expressed herein are those of management as of the date of publication and are subject to change without notice. Except for ongoing obligations of the Company to disclose material information under the federal securities laws, the Company does not undertake any obligation to release any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.
Christensen
Advisory
Christian Arnell
Phone: + 852 9040 0621
Email: christian.arnell@christensencomms.com
FAQ
What product did EUDA Health (EUDA) launch in this Form 6-K?
EUDA Health launched the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty face mask under its Helixé product line. The mask uses skin stem cell secretome and cellulose mask technology to support hydration, brightening, and overall skin recovery.
Who developed EUDA Health’s new Regenixé Mask and what rights does EUDA hold?
The Regenixé Mask was developed by Chemokine Pte Ltd, a Singapore-based biotech company. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine, covering this mask and other molecular supplement offerings in the Helixé line.
How large is the global face mask market cited by EUDA Health (EUDA)?
EUDA cites Mordor Intelligence data estimating the global face mask market at about US$7.95 billion in 2026, projected to reach roughly US$9.08 billion by 2031. This underscores the scale of the skincare and beauty opportunity the Regenixé Mask targets.
Which regions does EUDA Health plan to target for Regenixé Mask distribution?
EUDA plans to leverage its distribution networks and regional wellness partnerships in Malaysia and China to sell the Regenixé Mask. The company aims to expand the broader Helixé product line across the Asia-Pacific region, where demand for skincare is strong.
What is EUDA Health’s broader business focus beyond the Regenixé Mask?
EUDA Health is a Singapore-based provider focused on non-invasive and preventive healthcare in Singapore, Malaysia, and China. It targets the fast-growing longevity sector and aims to serve about 1.8 billion people in aging Asian populations with science-backed health solutions.
Does EUDA Health operate only in healthcare services?
No. In addition to non-invasive and preventive healthcare, EUDA Health also runs a Singapore-based property management business. This provides an additional operating segment alongside its core longevity and wellness-focused healthcare initiatives in Asia.